Related Experiment Video

Updated: Sep 1, 2025

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

411

Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention

Anne E O'Shea1, Franklin A Valdera1, Daniel Ensley2

  • 1Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, USA.

Clinical Immunology (Orlando, Fla.)
|August 16, 2022
PubMed

Insights

Rapamycin’s dual action on the immune system, inhibiting mTOR, offers both immunosuppression for transplant patients and immunostimulation for cancer treatment. Dosing and scheduling are key to harnessing its therapeutic potential in oncology.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Rapamycin targets the mechanistic target of rapamycin (mTOR) kinase, a key regulator of cell growth and immune responses.
  • mTOR inhibition by rapamycin exhibits both immunosuppressive and immunostimulatory effects.
  • Understanding these dual effects is crucial for optimizing rapamycin's therapeutic applications.

Purpose of the Study:

  • To explore the dual immunologic effects of rapamycin and its mechanistic target of rapamycin (mTOR) inhibition.
  • To investigate how dose and administration schedule influence rapamycin's immunomodulatory properties.
  • To evaluate the potential of rapamycin in cancer chemoprevention and treatment.

Main Methods:

  • Review of existing literature on rapamycin's effects on innate and adaptive immune responses.
  • Analysis of mTOR signaling pathways influenced by rapamycin.
  • Examination of clinical data regarding rapamycin's efficacy in transplant rejection and malignancy.

Main Results:

  • Rapamycin demonstrates both immunosuppressant and immunostimulatory effects via mTOR inhibition.
  • Lower doses and intermittent schedules of rapamycin promote immune function while mitigating toxicity.
  • Rapamycin's immunostimulatory properties contribute to its anti-neoplastic effects.

Conclusions:

  • Rapamycin's immunomodulatory profile is dose and schedule-dependent.
  • Optimized rapamycin therapy can leverage immunostimulatory effects for cancer prevention and treatment.
  • Rapamycin holds promise as a chemopreventive agent for various pre-malignant and low-grade malignant conditions.
Keywords:
ChemopreventionRapamycinmTOR

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.6K
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
646
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
258